StonvexLoading…
StonvexStonvexStonvexCore line items from ALGN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $4.03B | $4.00B | $3.86B | $3.73B |
Operating Income | $545.75M | $607.63M | $643.34M | $642.60M |
Net Income | $410.35M | $421.36M | $445.05M | $361.57M |
EPS (Diluted) | $5.65 | $5.62 | $5.81 | $4.61 |
Total Assets | $6.23B | $6.21B | $6.08B | $5.95B |
Total Liabilities | $2.18B | $2.36B | $2.45B | $2.35B |
Cash & Equivalents | $1.09B | $1.04B | $937.44M | $942.05M |
Free Cash Flow OCF − CapEx | $490.78M | $622.65M | $608.06M | $276.83M |
Shares Outstanding | 71.36M | 73.85M | 75.08M | 77.27M |